Pharma BD Deal Intelligence
A $96M all-cash acquisition that gave Merit Medical embolotherapy microspheres for uterine fibroids and hypervascular tumors. The deal achieved its stated rationale, though a 60/100 pipeline outcome score points to modest follow-through beyond the initial product fit.
Merit Medical / BioSphere Medical: Achieved Stated Rationale (Score: 65/100)
Full analysis, sources & comparables →Merit Medical signs agreement to acquire BioSphere Medical for $4.38 per share or approximately $96 million in all-cash transaction
Merit Medical Systems completes acquisition of BioSphere Medical gaining leading position in embolization therapies for interventional radiology
Merit Medical completes acquisition of BioSphere Medical gaining leading position in embolic treatment of uterine fibroids and tumors
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Merit Medical Systems acquired BioSphere Medical for approximately $96M in an all-cash transaction ($4.38 per share), gaining embolotherapy/embolic microsphere products for the treatment of uterine fibroids and hypervascular tumors.
Merit Medical / BioSphere Medical: Achieved Stated Rationale (Score: 65/100)
Assessment window: 5yr post-close.
600K US cases/yr · $1.0B US Embolization Market (2010)
BioSphere Medical pioneered bioengineered microspheres (Embosphere) for embolotherapy. Merit Medical's $96M acquisition added platform technology to its interventional radiology portfolio for uterine fibroids ($650M market) and liver cancer ($380M market).
Embosphere became a core Merit Medical product. Embolization market expanded with interventional oncology growth. Merit Medical grew to >$1.3B revenue by 2023.
Merit Medical Systems closes acquisition/merger of BIOSPHERE MEDICAL INC for $96M, establishing strategic position and initiating integration.
Strategic Fit: 75/100 | Financial Return: 65/100 | Pipeline Outcome: 60/100 | Integration: 68/100 | Deal Difficulty: 35/100. Achieved Stated Rationale overall outcome.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merit Medical Systems / BIOSPHERE MEDICAL INC (this deal) | 2010 | $96M | 64 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 2010 deals · Cardiovascular deals